Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 June 2020Website:
http://www.royaltypharma.comNext earnings report:
14 February 2025Last dividends:
15 November 2024Next dividends:
N/APrice
after hours | 41 min agoAnalysts recommendations
Institutional Ownership
Included in screeners
RPRX Latest News
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient's work.
Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy.
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.79 per share a year ago.
Royalty Pharma plc (NASDAQ:RPRX ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments Chris Hite - EVP, Vice Chairman Terry Coyne - EVP & CFO Conference Call Participants Hardik Parikh - JPMorgan Geoff Meacham - Citi Michael DiFiore - Evercore Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Chris Shibutani - Goldman Sachs Ash Verma - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter Earnings Conference Call.
Beyond analysts' top -and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share.
Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What type of business is Royalty Pharma?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
What sector is Royalty Pharma in?
Royalty Pharma is in the Healthcare sector
What industry is Royalty Pharma in?
Royalty Pharma is in the Biotechnology industry
What country is Royalty Pharma from?
Royalty Pharma is headquartered in United States
When did Royalty Pharma go public?
Royalty Pharma initial public offering (IPO) was on 16 June 2020
What is Royalty Pharma website?
https://www.royaltypharma.com
Is Royalty Pharma in the S&P 500?
No, Royalty Pharma is not included in the S&P 500 index
Is Royalty Pharma in the NASDAQ 100?
No, Royalty Pharma is not included in the NASDAQ 100 index
Is Royalty Pharma in the Dow Jones?
No, Royalty Pharma is not included in the Dow Jones index
When was Royalty Pharma the previous earnings report?
No data
When does Royalty Pharma earnings report?
The next expected earnings date for Royalty Pharma is 14 February 2025